Human Reproduction, Vol. 16, No. 4, 621-626,
April 2001
© 2001 European Society of Human Reproduction and Embryology
Poor responder–high responder: the importance of soluble vascular endothelial growth factor receptor 1 in ovarian stimulation protocols
1 Department of Gynecological Endocrinology and Reproductive Medicine, University Clinic, RWTH Aachen, 2 Ges. Biotechnologische Forschung, 3 Receptor Ligand Technologies GmbH (RELIATech), Braunschweig and 4 Department of Pathology, University Clinic, RWTH Aachen, Germany
This study was designed to detect vascular endothelial growth factor (VEGF) and its soluble receptor (sVEGFR-1) in follicular fluid specimens and to evaluate the importance of sVEGFR-1 with respect to ovarian response to gonadotrophin stimulation. A total of 69 patients was treated for IVF with recombinant human follicle stimulating hormone (FSH). Concentrations of VEGF and sVEGFR-1 were quantified in follicular fluids from oocyte retrievals. Patients were designated to three groups with respect to the number of harvested oocytes: group A, 1–5 oocytes; group B, 6–10 oocytes; group C, >10 oocytes. In group A, 1133 ± 870 pg VEGF/ml follicular fluid per oocyte were quantified, in group B 426 ± 262 pg VEGF/ml per oocyte, and in group C 274 ± 179 pg VEGF/ml per oocyte. Soluble VEGFR-1 concentrations resulted in 1200 ± 523 pg/ml follicular fluid per oocyte in group A, 255 ± 193 pg/ml per oocyte in group B, and 79 ± 69 pg/ml per oocyte in group C. No free sVEGFR-1 could be detected in any follicular fluid. An index to estimate the biological activity of VEGF by dividing VEGF/sVEGFR-1 revealed an increasing availability of VEGF with higher ovarian response to gonadotrophin therapy. In group A this index was 1.03, in group B 1.71, and in group C 3.21. A delicate balance between VEGF and sVEGFR-1 is necessary to allow an adequate ovarian reaction to gonadotrophin therapy. Excess of bio-active VEGF increases the risk for ovarian hyperstimulation syndrome. Excess of sVEGFR-1 results in poor response and goes in parallel with reduced chances for conception.
Key words: gonadotrophin therapy/ovarian function/sVEGFR-1/VEGF
5 To whom correspondence should be addressed at: Department of Gynecological Endocrinology and Reproductive Medicine,RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany. E-mail: jneulen{at}post.klinikum.rwth-aachen.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Bruegmann, R. Gruemmer, J. Neulen, and K. Motejlek Regulation of soluble vascular endothelial growth factor receptor 1 secretion from human endothelial cells by tissue inhibitor of metalloproteinase 1 Mol. Hum. Reprod., November 1, 2009; 15(11): 749 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Soares, R. Gomez, C. Simon, J. A. Garcia-Velasco, and A. Pellicer Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome Hum. Reprod. Update, April 2, 2008; (2008) dmn008v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Pau, I. Alonso-Muriel, R. Gomez, E. Novella, A. Ruiz, J. A. Garcia-Velasco, C. Simon, and A. Pellicer Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome Hum. Reprod., June 1, 2006; 21(6): 1453 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Classen-Linke, G. Muller-Newen, P.C. Heinrich, H.M. Beier, and U. von Rango The cytokine receptor gp130 and its soluble form are under hormonal control in human endometrium and decidua Mol. Hum. Reprod., July 1, 2004; 10(7): 495 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M.L. Ebos, G. Bocci, S. Man, P. E. Thorpe, D. J. Hicklin, D. Zhou, X. Jia, and R. S. Kerbel A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma Mol. Cancer Res., June 1, 2004; 2(6): 315 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gomez, C. Simon, J. Remohi, and A. Pellicer Administration of Moderate and High Doses of Gonadotropins to Female Rats Increases Ovarian Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor-2 Expression that Is Associated to Vascular Hyperpermeability Biol Reprod, June 1, 2003; 68(6): 2164 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.L. Luborsky, P. Thiruppathi, B. Rivnay, R. Roussev, C. Coulam, and E. Radwanska Evidence for different aetiologies of low estradiol response to FSH: age-related accelerated luteinization of follicles or presence of ovarian autoantibodies Hum. Reprod., October 1, 2002; 17(10): 2641 - 2649. [Abstract] [Full Text] [PDF]
|
|